2018 ASCO-SITC Clinical Immuno-Oncology Symposium January 25-27, 2018San Francisco Marriott MarquisSan Francisco, CAProgram SummaryDesigned for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focused on clinical and translational advances in immunooncology. At the 2018 Symposium, expert faculty offered new insights on the application of immunotherapy in melanoma, lung cancer, genitourinary cancers, head and neck cancer, and hematologic malignancies. Faculty also discussed considerations for clinical trial designs, the treatment of microsatellite instability high solid tumors, and emerging targets in immunotherapy. Abstract presentations featured in Oral Abstract Sessions and PosterSessions.Target AudienceThis Symposium was designed for physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists; nurses, pharmacists, advanced practice providers, and other health care professionals involved in clinical cancer care and cancer research in immuno-oncology.#Biomarkers #ClinicalTrials #ImmuneResponsiveness #TumorMicroenvironment #BladderCancer #GastrointestinalCancers #GenitourinaryCancers #HeadandNeckCancers #HematologicMalignancies #Leukemia #LungCancers #Melanoma #Myeloma #NonSmallCellLungCancer #OvarianCancer #ProstateCancer #RenalCellCarcinoma #PresentationSlides #Video #CollaborativeEvent #SITC #AdverseEvents #Toxicities #AdoptiveCellTherapy #CombinationTherapy #Cytokines #ImmuneCheckpointInhibitors #Pembrolizumab #Talimogenelaherparepvec #Clinician #NonPhysician #NursePractitioner #Oncologist #Pharmacist #Physician #RegisteredNurse #Researcher #2018
Meeting: ASCO-SITC Immuno-Oncology Symposium; Breakout Session I: Immunology 101 - The Basics; Presentation: Immunology 101: The Basics - Panel Discussion; Presenter: Mary L. (Nora) Disis, MD, FASCO - University of Washington; Date: January 25, 201800:17:05
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IX: Immune Therapies in Hematologic Malignancies - Strategies to Improve Efficacy and Reduce Toxicity; Presentation: How To Manage Cytokine Release Syndrome and Neurotoxicity Post CAR-T and BiTE Therapy; Presenter: Matthew J. Frigault, MD - Massachusetts General Hospital Cancer Center; Date: January 27, 201800:06:15
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IX: Immune Therapies in Hematologic Malignancies - Strategies to Improve Efficacy and Reduce Toxicity; Presentation: How To Manage Cytokine Release Syndrome and Neurotoxicity Post CAR-T and BiTE Therapy; Presenter: Matthew J. Frigault, MD - Massachusetts General Hospital Cancer Center; Date: January 27, 201800:16:03
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IX: Immune Therapies in Hematologic Malignancies - Strategies to Improve Efficacy and Reduce Toxicity; Presentation: The Future of Bispecifics for Hematologic Malignancies ; Presenter: Stephen Gottschalk, MD - St. Jude Children's Research Hospital; Date: January 27, 201800:14:15
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IX: Immune Therapies in Hematologic Malignancies - Strategies to Improve Efficacy and Reduce Toxicity; Presentation: Targeting B-Cell Malignancies with CAR T Cells: Beyond FDA Approval; Presenter: Marco L. Davila, MD, PhD - H. Lee Moffitt Cancer Center & Research Institute; Date: January 27, 201800:16:32
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session 9: Immune Therapies in Hematologic Malignancies - Strategies to Improve Efficacy and Reduce Toxicity; Presentation: Integrations of Immune Checkpoint Inhibitors in Hematologic Malignancies; Presenter: Stephen M. Ansell, MD, PhD - Mayo Clinic; Date: January 27, 201800:22:27
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VIII: Biomarkers - Insights into Mechanisms and Clinical Outcomes; Presentation: Panel Discussion; Date: January 27, 201800:15:38
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VIII: Biomarkers - Insights into Mechanisms and Clinical Outcomes; Presentation: Integrating the Immunoscore into Clinical Practice: Is It Ready for Prime Time?; Presenter: Bernard A. Fox, PhD - Earle A. Chiles Research Institute, Providence Cancer Center; Date: January 27, 201800:11:06
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VIII: Biomarkers - Insights into Mechanisms and Clinical Outcomes; Presentation: Tumor Genomic Signatures as Predictors of Clinical Response; Presenter: Carsten Denkert, MD, PhD - Charité University; Date: January 27, 201800:15:41
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VIII: Biomarkers - Insights into Mechanisms and Clinical Outcomes; Presentation: Multiplexed Immunohistochemistry: Insights into Immunotherapy Mechanisms of Action; Presenter: Kurt A. Schalper, MD, PhD - Yale School of Medicine; Date: January 27, 201800:17:03
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Discussion on Abstracts 103 and 104; Presenter: Ezra Cohen, MD, PhD - University of California, San Diego; Date: January 27, 201800:11:05
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Abstract 104: Expression of Endogenous Retroviruses and Response to Immune Checkpoint Therapy in Renal Cell Cancer; Presenter: Anshuman Panda, PhD - Rutgers Cancer Institute of New Jersey; Date: January 27, 201800:09:10
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Abstract 103: Exploration of the cGAS-STRING Pathway in Prostate Cancer; Presenter: Emma Reilly; Date: January 27, 201800:09:23
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Discussion of Abstracts 140 and 180; Presenter: Antoni Ribas, MD, PhD - University of California Los Angeles Medical Center; Date: January 27, 201800:08:10
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Abstract 180: MHC-II Expression to Drive a Unique Pattern of Adaptive Resistance to Anti tumor Immunity through Receptor Checkpoint Engagement; Presenter: Justin Balko, PhD, PharmD - Vanderbilt University Medical Center; Date: January 27, 201800:10:52
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session C: Biomarkers and Inflammatory Signatures; Presentation: Abstract 140: Association of the T-cell Receptor Landscape with Survival in Non-Small Cell Lung Cancer; Presenter: Alexandre Reuben, PhD - UT MD Anderson Cancer Center; Date: January 27, 201800:11:13
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: Panel Discussion; Presenter: Malcolm K. Brenner, MD, PhD - Baylor College of Medicine Texas Children's Hospital; Date: January 27, 201800:07:13
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: Should We Target Solid Tumors with CARs or TCRs?; Presenter: Malcolm K. Brenner, MD, PhD - Baylor College of Medicine Texas Children's Hospital; Date: January 27, 201800:34:58
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VII: Emerging Targets in Immunotherapy; Presentation: Panel Discussion; Date: January 27, 201800:15:48
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VII: Emerging Targets in Immunotherapy; Presentation: Optional Approaches to Translating CD40 as a Target in Pancreatic Cancer; Presenter: Katelyn T. Byrne, PhD - University of Pennsylvania; Date: January 27, 201800:13:15
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VII: Emerging Targets in Immunotherapy; Presentation: IDO Inhibition: Inhibiting the Inhibitors in Ovarian Cancer; Presenter: Kunle Odunsi, MD, PhD - Roswell Park Cancer Institute; Date: January 27, 201800:18:28
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VII: Emerging Targets in Immunotherapy; Presentation: Newer T-Cell Checkpoint Inhibitors: Used Independently and in Combination with Currently Approved Checkpoint Inhibitors; Presenter: Michael A. Postow, MD - Memorial Sloan Kettering Cancer Center; Date: January 27, 201800:15:49
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VII: Emerging Targets in Immunotherapy; Presentation: Welcome; Presenter: Mary L. (Nora) Disis, MD, FASCO - University of Washington; Date: January 27, 201800:02:49
Meeting: ASCO-SITC Immuno-Oncology Symposium; Evening Highlights: How Will Today's Presentations Impact Clinical Practice; Presentation: How Will Today's Presentations Impact Clinical Practice; Presenter: Robert Dreicer, MD, MS, MACP, FASCO - The University of Virginia Cancer Center; Date: January 26, 201800:24:10
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VI: Personalized Immunotherapy for Lung Cancer - Clinical Care, Markers and Combinations; Presentation: Panel Discussion; Date: January 26, 201800:20:35
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VI: Personalized Immunotherapy for Lung Cancer - Clinical Care, Markers and Combinations; Presentation: Using Combinations of Immunotherapy in Lung Cancer; Presenter: Roy S. Herbst, MD, PhD, FACP - Yale School of Medicine; Date: January 26, 201800:15:38
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VI: Personalized Immunotherapy for Lung Cancer - Clinical Care, Markers and Combinations; Presentation: Overcoming Primary and Acquired Immune Resistance in the Clinic; Presenter: Scott N. Gettinger, MD - Yale School of Medicine; Date: January 26, 201800:15:16
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VI: Personalized Immunotherapy for Lung Cancer - Clinical Care, Markers and Combinations; Presentation: Biomarkers for Activity of Immunotherapy in Lung Cancer; Presenter: Matthew D. Hellmann, MD - Memorial Sloan Kettering Cancer Center; Date: January 26, 201800:14:48
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session VI: Personalized Immunotherapy for Lung Cancer - Clinical Care, Markers and Combinations; Presentation: Integration of Immune Checkpoint Inhibitors in Lung Cancer; Presenter: Naiyer A. Rizvi, MD - Columbia University Medical Center; Date: January 26, 201800:22:18
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Discussion of Abstracts 121 and 122; Presenter: Malcolm K. Brenner, MD, PhD - Baylor College of Medicine Texas Children's Hospital; Date: January 26, 201800:09:58
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Abstract 122: Correlation of Patient Characteristics and Biomarkers with Clinical Outcomes of JCAR017 in R/R Aggressive B-NHL; Presenter: Tanya Siddiqui, MD; Date: January 26, 201800:09:27
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Abstract 121: Targeting CD19-negative Relapsed B-acute Lymphoblastic Leukemia Using Trivalent CAR T Cells; Presenter: Kristen Fousek - Baylor College of Medicine; Date: January 26, 201800:09:36
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Discussion of Abstract 50 and Abstract 120; Presenter: Stephen Gottschalk, MD - St. Jude Children's Research Hospital; Date: January 26, 201800:09:46
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Abstract 120: High durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive b-NHL: A Defined Composition CD19-Directed CART T-cell Product with potential for Outpatient Administration; Presenter: Jeremy Abramson, MD - Massachusetts General Hospital Cancer Center; Date: January 26, 201800:11:39
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstracts Session B: CAR-T Cells; Presentation: Abstract 50: Capturing the Complexity of the Immune Microenvironment of Acute Myeloid Leukemia with 3D Biology Technology; Presenter: Sergio Rutella, MD, PhD, FRCPath - The John van Geest Cancer Research Centre; Date: January 26, 201800:09:43
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: Clinical Developments in Immunogenetics; Presenter: Luis A. Diaz, Jr., MD - Memorial Sloan Kettering Cancer Center; Date: January 26, 201800:11:59
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: Clinical Developments in Immunogenetics; Presenter: Luis A. Diaz, Jr., MD - Memorial Sloan Kettering Cancer Center; Date: January 26, 201800:32:42
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session V: Using Genomic Profiling for Tumor Immunotherapy - New Paradigms for the Treatment of Microsatellite Instability High Solid Tumors; Presentation: Panel Discussion; Date: January 26, 201800:15:47
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session V: Using Genomic Profiling for Tumor Immunotherapy - New Paradigms for the Treatment of Microsatellite Instability High Solid Tumors; Presentation: Implications of Pembrolizumab Approval for MSI-High Solid Tumors; Presenter: E. Gabriela Chiorean, MD - Fred Hutchinson Cancer Research Center; Date: January 26, 201800:14:47
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session V: Using Genomic Profiling for Tumor Immunotherapy - New Paradigms for the Treatment of Microsatellite Instability High Solid Tumors; Presentation: Integrating Immunotherapy into the Treatment of Patients with MSI-High Solid Tumors; Presenter: Dung T. Le, MD - Johns Hopkins University; Date: January 26, 201800:15:30
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session V: Using Genomic Profiling for Tumor Immunotherapy - New Paradigms for the Treatment of Microsatellite Instability High Solid Tumors; Presentation: How Can Genomics Guide Decision Making in the Application of Immunotherapy?; Presenter: Colin Pritchard, MD, PhD - University of Washington; Date: January 26, 201800:15:21
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies; Presentation: Panel Discussion; Date: January 26, 201800:29:30
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies; Presentation: Expanding Options in the Immunotherapy of Prostate Cancer; Presenter: James L. Gulley, MD, PhD, FACP - National Cancer Institute; Date: January 26, 201800:16:58
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies; Presentation: Latest Developments in the Immunotherapy of Renal Cancer; Presenter: Sumanta K. Pal, MD - City of Hope Comprehensive Cancer Center; Date: January 26, 201800:15:22
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies; Presentation: Refining Choices and Sequencing of Therapy in Bladder Cancer; Presenter: Joaquim Bellmunt, MD, PhD - Dana-Farber Cancer Institute; Date: January 26, 201800:17:13
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies; Presentation: The Use of Checkpoint Blockade in Non-Muscle Invasive Bladder Cancer; Presenter: Colin P.N. Dinnery, MD - The University of Texas MD Anderson Cancer Center; Date: January 26, 201800:17:30
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session IV: Expanding Options in Genitourinary Malignancies ; Presentation: Welcome; Presenter: Antoni Ribas, MD, PhD - University of California Los Angeles Medical Center; Date: January 26, 201800:05:36
Meeting: ASCO-SITC Immuno-Oncology Symposium; Immunology 101: Tools and Assays Used in Clinical Trials; Presentation: Panel Discussion; Presenter: Elad Sharon, MD, MPH - National Cancer Institute; Date: January 26, 201800:10:20
Meeting: ASCO-SITC Immuno-Oncology Symposium; Immunology 101: Tools and Assays Used in Clinical Trials; Presentation: Immunology 101: Tools and Assays Used in Clinical Trials; Presenter: Elad Sharon, MD, MPH - National Cancer Institute; Date: January 26, 201800:32:08
Meeting: ASCO-SITC Immuno-Oncology Symposium; Evening Highlights; Presentation: How Will Today's Presentations Impact Clinical Practice? ; Presenter: Katy K. Tsai, MD - University of California, San Francisco; Date: January 25, 201800:18:17
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Panel Discussion; Date: January 25, 201800:13:16
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Discussion of Abstracts 47 and 20; Presenter: Ravindra Uppaluri, MD, PhD - Brigham and Women's Hospital and Dana-Farber Cancer Institute; Date: January 25, 201800:11:12
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Abstract 20: Safety and Clinical Activity of pembrolizumab Immunotherapy and Multiorgan Site Ablative Stereotactic Body Radiotherapy (iMOSART) in Patients with Advanced Solid Tumors; Presenter: Jeffrey Lemons, MD; Date: January 25, 201800:07:29
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Abstract 47: Analysis of over 100,000 Patients with Cancer For CD274 (PD-L1) Amplification: Implications for Treatment with Immune Checkpoint Blockade; Presenter: Aaron Goodman, MD - American Head and Neck Society; Date: January 25, 201800:10:03
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Interplay of Radiation and Immunotherapy in Head and Neck Cancers; Presenter: Marka R. Crittenden, MD, PhD - Earle A. Chiles Research Institute, Providence Cancer Center; Date: January 25, 201800:15:22
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Overcoming the Immunosuppressive Tumor Microenvironment in Head and Neck Cancers; Presenter: Andrew G. Sikora, MD, PhD, MRCP - Baylor College of Medicine; Date: January 25, 201800:16:06
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session III: Integrating Immunotherapy into the Management of Head and Neck Cancers; Presentation: Welcome; Presenter: Ezra E.W.Cohen, MD, FRCPC, FASCO - University of California, San Diego; Date: January 25, 201800:16:16
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session A: Clinical Trials; Presentation: Discussion of Abstract 49; Presenter:Ann W. Silk, MD - Rutgers Cancer Institute of New Jersey; Date: January 25, 201800:07:57
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session A: Clinical Trials; Presentation: Abstract 49: Phase 1 Study of E7046, a Novel PGE2 Receptor Type 4 Inhibitor, in Patients with Advanced Solid Tumors: Clinical Results and Effects on Myeloid-and T-Lymphoid Cell-Mediated Immunosuppression; Presenter: David Hong, MD - The University of Texas MD Anderson Cancer Center; Date: January 25, 201800:08:08
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session A: Clinical Trials; Presentation: Discussion of Abstracts 48 and 139; Presenter: Deborah J. L. Wong, MD, PhD - University of California, Los Angeles; Date: January 25, 201800:12:27
Meeting: ASCO-SITC Immuno-Oncology Symposium; Oral Abstract Session A: Clinical Trials; Presentation: Abstract 139: Whole Body PD-L1 PET in Patients with NSCLC and Melanoma; Presenter: David Leung; Date: January 25, 201800:09:11
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: Abstract 48: A Phase 1b Study of the Anti-PD-1 Monoclonal Antibody BGB-A317 (A317) in Combination with the PARP Inhibitor BGB-290 (290) in Advanced Solid Tumors; Presenter: Michael Friedlander, MD, PhD - Prince of Wales Hospital; Date: January 25, 201800:10:40
Meeting: ASCO-SITC Immuno-Oncology Symposium; Keynote Lecture; Presentation: The Future of Cancer Immunotherapy; Presenter: Jeffrey Bluestone, PhD - Parker Institute for Cancer Immunotherapy and University of California, San Francisco; Date: January 25, 201800:38:17
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session II: Considerations for Clinical Trial Designs; Presentation: Panel Discussion Date: January 25, 201800:11:38
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session II: Considerations for Clinical Trial Designs; Presentation: Selection and Testing of Optimal Correlates of Immunotherapy: Optional or Critical. Integrated or Integral?; Presenter: Lisa H. Butterfield, PhD - University of Pittsburgh; Date: January 25, 201800:16:33
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session II: Considerations for Clinical Trial Designs; Presentation: Trial Design for Early-Phase Testing of New Agents; Presenter: Shivaani Kummar, MD, FACP - Stanford University Medical Center; Date: January 25, 201800:15:08
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session II: Considerations for Clinical Trial Designs; Presentation: Principles of Cancer Trial Design in the Era of Immunotherapy and Molecular Targets for Cancer ; Presenter: Johann S. De Bono, MD, PhD, FRCP - The Institute of Cancer Research and the Royal Marsden Hospital; Date: January 25, 201800:18:54
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session I: Pushing the Envelope with Melanoma Immunotherapy; Presentation: Panel Discussion; Date: January 25, 201800:25:30
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session I: Pushing the Envelope with Melanoma Immunotherapy; Presentation: Immunotherapy to Treat Metastatic Melanoma to the Brain; Presenter: Sunandana Chandra, MD, MS - Northwestern University; Date: January 25, 201800:20:39
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session I: Pushing the Envelope with Melanoma Immunotherapy; Presentation: How Melanoma Resists Immune Attack and Implications for Treatment; Presenter: Antoni Ribas, MD, PhD - University of California Los Angeles Medical Center; Date: January 25, 201800:21:18
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session I: Pushing the Envelope with Melanoma Immunotherapy; Presentation: Integration of Immune Checkpoint Inhibitors in Melanoma; Presenter: Katy K. Tsai, MD - University of California, San Francisco; Date: January 25, 201800:23:43
Meeting: ASCO-SITC Immuno-Oncology Symposium; General Session I: Pushing the Envelope with Melanoma Immunotherapy; Presentation: Weclome; Presenter: Mary L. (Nora) Disis, MD, FASCO - University of Washington; Date: January 25, 201800:06:22
Meeting: ASCO-SITC Immuno-Oncology Symposium; Breakout Session I: Immunology 101 - The Basics; Presentation: Immunology 101: The Basics; Presenter: Mary L. (Nora) Disis, MD, FASCO - University of Washington; Date: January 25, 201800:30:40